nodes	percent_of_prediction	percent_of_DWPC	metapath
Labetalol—CYP2D6—Lomustine—hematologic cancer	0.0751	0.189	CbGbCtD
Labetalol—CYP2D6—Idarubicin—hematologic cancer	0.0669	0.168	CbGbCtD
Labetalol—CYP2D6—Hydroxyurea—hematologic cancer	0.0569	0.143	CbGbCtD
Labetalol—CYP2D6—Bortezomib—hematologic cancer	0.0495	0.124	CbGbCtD
Labetalol—CYP2D6—Imatinib—hematologic cancer	0.0363	0.0912	CbGbCtD
Labetalol—CYP2D6—Nilotinib—hematologic cancer	0.033	0.0829	CbGbCtD
Labetalol—CYP2D6—Vinorelbine—hematologic cancer	0.0327	0.0822	CbGbCtD
Labetalol—CYP2D6—Vinblastine—hematologic cancer	0.0201	0.0506	CbGbCtD
Labetalol—CYP2D6—Dexamethasone—hematologic cancer	0.0149	0.0375	CbGbCtD
Labetalol—CYP2D6—Doxorubicin—hematologic cancer	0.0124	0.0311	CbGbCtD
Labetalol—Isoprenaline—PIK3R1—hematologic cancer	0.00262	0.474	CrCbGaD
Labetalol—Benazepril—MTHFR—hematologic cancer	0.000788	0.143	CrCbGaD
Labetalol—Flurbiprofen—UGT1A1—hematologic cancer	0.000635	0.115	CrCbGaD
Labetalol—Mirabegron—ALB—hematologic cancer	0.000399	0.0723	CrCbGaD
Labetalol—Mirabegron—ABCB1—hematologic cancer	0.000381	0.069	CrCbGaD
Labetalol—Fenoprofen—ALB—hematologic cancer	0.000238	0.0432	CrCbGaD
Labetalol—Propafenone—ABCB1—hematologic cancer	0.00017	0.0308	CrCbGaD
Labetalol—Flurbiprofen—ALB—hematologic cancer	0.000156	0.0282	CrCbGaD
Labetalol—Ketoprofen—ALB—hematologic cancer	0.000141	0.0255	CrCbGaD
Labetalol—Urticaria—Prednisolone—hematologic cancer	9.17e-05	0.000179	CcSEcCtD
Labetalol—Asthenia—Cisplatin—hematologic cancer	9.16e-05	0.000179	CcSEcCtD
Labetalol—Fatigue—Triamcinolone—hematologic cancer	9.15e-05	0.000179	CcSEcCtD
Labetalol—Sweating—Doxorubicin—hematologic cancer	9.12e-05	0.000179	CcSEcCtD
Labetalol—Rash—Vincristine—hematologic cancer	9.11e-05	0.000178	CcSEcCtD
Labetalol—Dermatitis—Vincristine—hematologic cancer	9.1e-05	0.000178	CcSEcCtD
Labetalol—Oedema peripheral—Epirubicin—hematologic cancer	9.09e-05	0.000178	CcSEcCtD
Labetalol—Pain—Triamcinolone—hematologic cancer	9.07e-05	0.000178	CcSEcCtD
Labetalol—Headache—Vincristine—hematologic cancer	9.05e-05	0.000177	CcSEcCtD
Labetalol—Loss of consciousness—Prednisone—hematologic cancer	9.03e-05	0.000177	CcSEcCtD
Labetalol—Hypotension—Betamethasone—hematologic cancer	9e-05	0.000176	CcSEcCtD
Labetalol—Hypotension—Dexamethasone—hematologic cancer	9e-05	0.000176	CcSEcCtD
Labetalol—Nausea—Carmustine—hematologic cancer	8.99e-05	0.000176	CcSEcCtD
Labetalol—Epistaxis—Doxorubicin—hematologic cancer	8.97e-05	0.000176	CcSEcCtD
Labetalol—Vomiting—Mitoxantrone—hematologic cancer	8.94e-05	0.000175	CcSEcCtD
Labetalol—Vomiting—Irinotecan—hematologic cancer	8.94e-05	0.000175	CcSEcCtD
Labetalol—Nausea—Alitretinoin—hematologic cancer	8.9e-05	0.000174	CcSEcCtD
Labetalol—Visual impairment—Epirubicin—hematologic cancer	8.89e-05	0.000174	CcSEcCtD
Labetalol—Agranulocytosis—Doxorubicin—hematologic cancer	8.88e-05	0.000174	CcSEcCtD
Labetalol—Hypertension—Prednisone—hematologic cancer	8.87e-05	0.000174	CcSEcCtD
Labetalol—Rash—Mitoxantrone—hematologic cancer	8.87e-05	0.000174	CcSEcCtD
Labetalol—Rash—Irinotecan—hematologic cancer	8.87e-05	0.000174	CcSEcCtD
Labetalol—Dermatitis—Irinotecan—hematologic cancer	8.86e-05	0.000173	CcSEcCtD
Labetalol—Dermatitis—Mitoxantrone—hematologic cancer	8.86e-05	0.000173	CcSEcCtD
Labetalol—Headache—Irinotecan—hematologic cancer	8.81e-05	0.000172	CcSEcCtD
Labetalol—Headache—Mitoxantrone—hematologic cancer	8.81e-05	0.000172	CcSEcCtD
Labetalol—Nausea—Ifosfamide—hematologic cancer	8.8e-05	0.000172	CcSEcCtD
Labetalol—Feeling abnormal—Triamcinolone—hematologic cancer	8.74e-05	0.000171	CcSEcCtD
Labetalol—Diarrhoea—Cisplatin—hematologic cancer	8.74e-05	0.000171	CcSEcCtD
Labetalol—Alopecia—Methotrexate—hematologic cancer	8.72e-05	0.000171	CcSEcCtD
Labetalol—Vomiting—Gemcitabine—hematologic cancer	8.71e-05	0.000171	CcSEcCtD
Labetalol—Bradycardia—Doxorubicin—hematologic cancer	8.69e-05	0.00017	CcSEcCtD
Labetalol—Paraesthesia—Betamethasone—hematologic cancer	8.65e-05	0.000169	CcSEcCtD
Labetalol—Paraesthesia—Dexamethasone—hematologic cancer	8.65e-05	0.000169	CcSEcCtD
Labetalol—Discomfort—Prednisone—hematologic cancer	8.64e-05	0.000169	CcSEcCtD
Labetalol—Mental disorder—Methotrexate—hematologic cancer	8.64e-05	0.000169	CcSEcCtD
Labetalol—Rash—Gemcitabine—hematologic cancer	8.64e-05	0.000169	CcSEcCtD
Labetalol—Dermatitis—Gemcitabine—hematologic cancer	8.63e-05	0.000169	CcSEcCtD
Labetalol—Hypersensitivity—Etoposide—hematologic cancer	8.62e-05	0.000169	CcSEcCtD
Labetalol—Erythema—Methotrexate—hematologic cancer	8.59e-05	0.000168	CcSEcCtD
Labetalol—Headache—Gemcitabine—hematologic cancer	8.58e-05	0.000168	CcSEcCtD
Labetalol—Nausea—Vincristine—hematologic cancer	8.58e-05	0.000168	CcSEcCtD
Labetalol—Flushing—Epirubicin—hematologic cancer	8.57e-05	0.000168	CcSEcCtD
Labetalol—Hepatitis—Doxorubicin—hematologic cancer	8.54e-05	0.000167	CcSEcCtD
Labetalol—Hypersensitivity—Prednisolone—hematologic cancer	8.5e-05	0.000166	CcSEcCtD
Labetalol—Hypoaesthesia—Doxorubicin—hematologic cancer	8.5e-05	0.000166	CcSEcCtD
Labetalol—Dyspepsia—Betamethasone—hematologic cancer	8.47e-05	0.000166	CcSEcCtD
Labetalol—Dyspepsia—Dexamethasone—hematologic cancer	8.47e-05	0.000166	CcSEcCtD
Labetalol—Urticaria—Triamcinolone—hematologic cancer	8.43e-05	0.000165	CcSEcCtD
Labetalol—Oedema peripheral—Doxorubicin—hematologic cancer	8.41e-05	0.000165	CcSEcCtD
Labetalol—Asthenia—Etoposide—hematologic cancer	8.39e-05	0.000164	CcSEcCtD
Labetalol—Body temperature increased—Triamcinolone—hematologic cancer	8.39e-05	0.000164	CcSEcCtD
Labetalol—Anaphylactic shock—Prednisone—hematologic cancer	8.38e-05	0.000164	CcSEcCtD
Labetalol—Oedema—Prednisone—hematologic cancer	8.38e-05	0.000164	CcSEcCtD
Labetalol—Nausea—Mitoxantrone—hematologic cancer	8.35e-05	0.000164	CcSEcCtD
Labetalol—Nausea—Irinotecan—hematologic cancer	8.35e-05	0.000164	CcSEcCtD
Labetalol—Fatigue—Dexamethasone—hematologic cancer	8.3e-05	0.000162	CcSEcCtD
Labetalol—Fatigue—Betamethasone—hematologic cancer	8.3e-05	0.000162	CcSEcCtD
Labetalol—Pruritus—Etoposide—hematologic cancer	8.28e-05	0.000162	CcSEcCtD
Labetalol—Shock—Prednisone—hematologic cancer	8.25e-05	0.000161	CcSEcCtD
Labetalol—Pain—Betamethasone—hematologic cancer	8.23e-05	0.000161	CcSEcCtD
Labetalol—Pain—Dexamethasone—hematologic cancer	8.23e-05	0.000161	CcSEcCtD
Labetalol—Visual impairment—Doxorubicin—hematologic cancer	8.23e-05	0.000161	CcSEcCtD
Labetalol—Alopecia—Epirubicin—hematologic cancer	8.16e-05	0.00016	CcSEcCtD
Labetalol—Nausea—Gemcitabine—hematologic cancer	8.14e-05	0.000159	CcSEcCtD
Labetalol—Vomiting—Cisplatin—hematologic cancer	8.12e-05	0.000159	CcSEcCtD
Labetalol—Hyperhidrosis—Prednisone—hematologic cancer	8.11e-05	0.000159	CcSEcCtD
Labetalol—Vision blurred—Methotrexate—hematologic cancer	8.09e-05	0.000158	CcSEcCtD
Labetalol—Mental disorder—Epirubicin—hematologic cancer	8.09e-05	0.000158	CcSEcCtD
Labetalol—Rash—Cisplatin—hematologic cancer	8.05e-05	0.000158	CcSEcCtD
Labetalol—Dermatitis—Cisplatin—hematologic cancer	8.04e-05	0.000157	CcSEcCtD
Labetalol—Erythema—Epirubicin—hematologic cancer	8.03e-05	0.000157	CcSEcCtD
Labetalol—Diarrhoea—Etoposide—hematologic cancer	8e-05	0.000157	CcSEcCtD
Labetalol—Ill-defined disorder—Methotrexate—hematologic cancer	7.97e-05	0.000156	CcSEcCtD
Labetalol—Feeling abnormal—Dexamethasone—hematologic cancer	7.93e-05	0.000155	CcSEcCtD
Labetalol—Feeling abnormal—Betamethasone—hematologic cancer	7.93e-05	0.000155	CcSEcCtD
Labetalol—Flushing—Doxorubicin—hematologic cancer	7.93e-05	0.000155	CcSEcCtD
Labetalol—Gastrointestinal pain—Betamethasone—hematologic cancer	7.87e-05	0.000154	CcSEcCtD
Labetalol—Gastrointestinal pain—Dexamethasone—hematologic cancer	7.87e-05	0.000154	CcSEcCtD
Labetalol—Hypersensitivity—Triamcinolone—hematologic cancer	7.82e-05	0.000153	CcSEcCtD
Labetalol—Malaise—Methotrexate—hematologic cancer	7.74e-05	0.000152	CcSEcCtD
Labetalol—Dizziness—Etoposide—hematologic cancer	7.74e-05	0.000151	CcSEcCtD
Labetalol—Muscle spasms—Epirubicin—hematologic cancer	7.72e-05	0.000151	CcSEcCtD
Labetalol—Vertigo—Methotrexate—hematologic cancer	7.71e-05	0.000151	CcSEcCtD
Labetalol—Urticaria—Betamethasone—hematologic cancer	7.65e-05	0.00015	CcSEcCtD
Labetalol—Urticaria—Dexamethasone—hematologic cancer	7.65e-05	0.00015	CcSEcCtD
Labetalol—Dizziness—Prednisolone—hematologic cancer	7.63e-05	0.000149	CcSEcCtD
Labetalol—Asthenia—Triamcinolone—hematologic cancer	7.61e-05	0.000149	CcSEcCtD
Labetalol—Body temperature increased—Betamethasone—hematologic cancer	7.61e-05	0.000149	CcSEcCtD
Labetalol—Abdominal pain—Dexamethasone—hematologic cancer	7.61e-05	0.000149	CcSEcCtD
Labetalol—Abdominal pain—Betamethasone—hematologic cancer	7.61e-05	0.000149	CcSEcCtD
Labetalol—Body temperature increased—Dexamethasone—hematologic cancer	7.61e-05	0.000149	CcSEcCtD
Labetalol—Nausea—Cisplatin—hematologic cancer	7.58e-05	0.000148	CcSEcCtD
Labetalol—Vision blurred—Epirubicin—hematologic cancer	7.57e-05	0.000148	CcSEcCtD
Labetalol—Alopecia—Doxorubicin—hematologic cancer	7.55e-05	0.000148	CcSEcCtD
Labetalol—Paraesthesia—Prednisone—hematologic cancer	7.53e-05	0.000147	CcSEcCtD
Labetalol—Pruritus—Triamcinolone—hematologic cancer	7.51e-05	0.000147	CcSEcCtD
Labetalol—Mental disorder—Doxorubicin—hematologic cancer	7.48e-05	0.000146	CcSEcCtD
Labetalol—Ill-defined disorder—Epirubicin—hematologic cancer	7.46e-05	0.000146	CcSEcCtD
Labetalol—Vomiting—Etoposide—hematologic cancer	7.44e-05	0.000146	CcSEcCtD
Labetalol—Erythema—Doxorubicin—hematologic cancer	7.43e-05	0.000146	CcSEcCtD
Labetalol—Dyspepsia—Prednisone—hematologic cancer	7.38e-05	0.000144	CcSEcCtD
Labetalol—Rash—Etoposide—hematologic cancer	7.38e-05	0.000144	CcSEcCtD
Labetalol—Dermatitis—Etoposide—hematologic cancer	7.37e-05	0.000144	CcSEcCtD
Labetalol—Headache—Etoposide—hematologic cancer	7.33e-05	0.000143	CcSEcCtD
Labetalol—Rash—Prednisolone—hematologic cancer	7.28e-05	0.000142	CcSEcCtD
Labetalol—Dermatitis—Prednisolone—hematologic cancer	7.27e-05	0.000142	CcSEcCtD
Labetalol—Malaise—Epirubicin—hematologic cancer	7.25e-05	0.000142	CcSEcCtD
Labetalol—Fatigue—Prednisone—hematologic cancer	7.23e-05	0.000142	CcSEcCtD
Labetalol—Headache—Prednisolone—hematologic cancer	7.23e-05	0.000142	CcSEcCtD
Labetalol—Discomfort—Methotrexate—hematologic cancer	7.22e-05	0.000141	CcSEcCtD
Labetalol—Vertigo—Epirubicin—hematologic cancer	7.22e-05	0.000141	CcSEcCtD
Labetalol—Syncope—Epirubicin—hematologic cancer	7.21e-05	0.000141	CcSEcCtD
Labetalol—Constipation—Prednisone—hematologic cancer	7.17e-05	0.00014	CcSEcCtD
Labetalol—Muscle spasms—Doxorubicin—hematologic cancer	7.15e-05	0.00014	CcSEcCtD
Labetalol—Palpitations—Epirubicin—hematologic cancer	7.1e-05	0.000139	CcSEcCtD
Labetalol—Confusional state—Methotrexate—hematologic cancer	7.07e-05	0.000138	CcSEcCtD
Labetalol—Loss of consciousness—Epirubicin—hematologic cancer	7.06e-05	0.000138	CcSEcCtD
Labetalol—Dizziness—Triamcinolone—hematologic cancer	7.02e-05	0.000137	CcSEcCtD
Labetalol—Anaphylactic shock—Methotrexate—hematologic cancer	7.01e-05	0.000137	CcSEcCtD
Labetalol—Vision blurred—Doxorubicin—hematologic cancer	7.01e-05	0.000137	CcSEcCtD
Labetalol—Nausea—Etoposide—hematologic cancer	6.95e-05	0.000136	CcSEcCtD
Labetalol—Hypertension—Epirubicin—hematologic cancer	6.94e-05	0.000136	CcSEcCtD
Labetalol—Feeling abnormal—Prednisone—hematologic cancer	6.91e-05	0.000135	CcSEcCtD
Labetalol—Asthenia—Betamethasone—hematologic cancer	6.91e-05	0.000135	CcSEcCtD
Labetalol—Asthenia—Dexamethasone—hematologic cancer	6.91e-05	0.000135	CcSEcCtD
Labetalol—Ill-defined disorder—Doxorubicin—hematologic cancer	6.9e-05	0.000135	CcSEcCtD
Labetalol—Gastrointestinal pain—Prednisone—hematologic cancer	6.86e-05	0.000134	CcSEcCtD
Labetalol—Nausea—Prednisolone—hematologic cancer	6.85e-05	0.000134	CcSEcCtD
Labetalol—Pruritus—Dexamethasone—hematologic cancer	6.81e-05	0.000133	CcSEcCtD
Labetalol—Pruritus—Betamethasone—hematologic cancer	6.81e-05	0.000133	CcSEcCtD
Labetalol—Hyperhidrosis—Methotrexate—hematologic cancer	6.77e-05	0.000133	CcSEcCtD
Labetalol—Discomfort—Epirubicin—hematologic cancer	6.76e-05	0.000132	CcSEcCtD
Labetalol—Vomiting—Triamcinolone—hematologic cancer	6.75e-05	0.000132	CcSEcCtD
Labetalol—Malaise—Doxorubicin—hematologic cancer	6.7e-05	0.000131	CcSEcCtD
Labetalol—Rash—Triamcinolone—hematologic cancer	6.69e-05	0.000131	CcSEcCtD
Labetalol—Dermatitis—Triamcinolone—hematologic cancer	6.68e-05	0.000131	CcSEcCtD
Labetalol—Vertigo—Doxorubicin—hematologic cancer	6.68e-05	0.000131	CcSEcCtD
Labetalol—Syncope—Doxorubicin—hematologic cancer	6.67e-05	0.000131	CcSEcCtD
Labetalol—Urticaria—Prednisone—hematologic cancer	6.66e-05	0.00013	CcSEcCtD
Labetalol—Headache—Triamcinolone—hematologic cancer	6.65e-05	0.00013	CcSEcCtD
Labetalol—Abdominal pain—Prednisone—hematologic cancer	6.63e-05	0.00013	CcSEcCtD
Labetalol—Body temperature increased—Prednisone—hematologic cancer	6.63e-05	0.00013	CcSEcCtD
Labetalol—Confusional state—Epirubicin—hematologic cancer	6.61e-05	0.000129	CcSEcCtD
Labetalol—Diarrhoea—Dexamethasone—hematologic cancer	6.59e-05	0.000129	CcSEcCtD
Labetalol—Diarrhoea—Betamethasone—hematologic cancer	6.59e-05	0.000129	CcSEcCtD
Labetalol—Palpitations—Doxorubicin—hematologic cancer	6.57e-05	0.000129	CcSEcCtD
Labetalol—Oedema—Epirubicin—hematologic cancer	6.56e-05	0.000128	CcSEcCtD
Labetalol—Anaphylactic shock—Epirubicin—hematologic cancer	6.56e-05	0.000128	CcSEcCtD
Labetalol—Hypotension—Methotrexate—hematologic cancer	6.55e-05	0.000128	CcSEcCtD
Labetalol—Loss of consciousness—Doxorubicin—hematologic cancer	6.53e-05	0.000128	CcSEcCtD
Labetalol—Shock—Epirubicin—hematologic cancer	6.45e-05	0.000126	CcSEcCtD
Labetalol—Hypertension—Doxorubicin—hematologic cancer	6.42e-05	0.000126	CcSEcCtD
Labetalol—Dizziness—Dexamethasone—hematologic cancer	6.37e-05	0.000125	CcSEcCtD
Labetalol—Dizziness—Betamethasone—hematologic cancer	6.37e-05	0.000125	CcSEcCtD
Labetalol—Hyperhidrosis—Epirubicin—hematologic cancer	6.34e-05	0.000124	CcSEcCtD
Labetalol—Nausea—Triamcinolone—hematologic cancer	6.3e-05	0.000123	CcSEcCtD
Labetalol—Paraesthesia—Methotrexate—hematologic cancer	6.29e-05	0.000123	CcSEcCtD
Labetalol—Discomfort—Doxorubicin—hematologic cancer	6.25e-05	0.000122	CcSEcCtD
Labetalol—Dyspnoea—Methotrexate—hematologic cancer	6.25e-05	0.000122	CcSEcCtD
Labetalol—Somnolence—Methotrexate—hematologic cancer	6.23e-05	0.000122	CcSEcCtD
Labetalol—Hypersensitivity—Prednisone—hematologic cancer	6.18e-05	0.000121	CcSEcCtD
Labetalol—Dyspepsia—Methotrexate—hematologic cancer	6.17e-05	0.000121	CcSEcCtD
Labetalol—Hypotension—Epirubicin—hematologic cancer	6.13e-05	0.00012	CcSEcCtD
Labetalol—Vomiting—Dexamethasone—hematologic cancer	6.12e-05	0.00012	CcSEcCtD
Labetalol—Vomiting—Betamethasone—hematologic cancer	6.12e-05	0.00012	CcSEcCtD
Labetalol—Confusional state—Doxorubicin—hematologic cancer	6.12e-05	0.00012	CcSEcCtD
Labetalol—Rash—Dexamethasone—hematologic cancer	6.07e-05	0.000119	CcSEcCtD
Labetalol—Rash—Betamethasone—hematologic cancer	6.07e-05	0.000119	CcSEcCtD
Labetalol—Anaphylactic shock—Doxorubicin—hematologic cancer	6.07e-05	0.000119	CcSEcCtD
Labetalol—Oedema—Doxorubicin—hematologic cancer	6.07e-05	0.000119	CcSEcCtD
Labetalol—Dermatitis—Betamethasone—hematologic cancer	6.06e-05	0.000119	CcSEcCtD
Labetalol—Dermatitis—Dexamethasone—hematologic cancer	6.06e-05	0.000119	CcSEcCtD
Labetalol—Fatigue—Methotrexate—hematologic cancer	6.04e-05	0.000118	CcSEcCtD
Labetalol—Headache—Betamethasone—hematologic cancer	6.03e-05	0.000118	CcSEcCtD
Labetalol—Headache—Dexamethasone—hematologic cancer	6.03e-05	0.000118	CcSEcCtD
Labetalol—Asthenia—Prednisone—hematologic cancer	6.02e-05	0.000118	CcSEcCtD
Labetalol—Pain—Methotrexate—hematologic cancer	5.99e-05	0.000117	CcSEcCtD
Labetalol—Shock—Doxorubicin—hematologic cancer	5.97e-05	0.000117	CcSEcCtD
Labetalol—Pruritus—Prednisone—hematologic cancer	5.93e-05	0.000116	CcSEcCtD
Labetalol—Paraesthesia—Epirubicin—hematologic cancer	5.89e-05	0.000115	CcSEcCtD
Labetalol—Hyperhidrosis—Doxorubicin—hematologic cancer	5.87e-05	0.000115	CcSEcCtD
Labetalol—Dyspnoea—Epirubicin—hematologic cancer	5.85e-05	0.000114	CcSEcCtD
Labetalol—Somnolence—Epirubicin—hematologic cancer	5.83e-05	0.000114	CcSEcCtD
Labetalol—Feeling abnormal—Methotrexate—hematologic cancer	5.77e-05	0.000113	CcSEcCtD
Labetalol—Dyspepsia—Epirubicin—hematologic cancer	5.77e-05	0.000113	CcSEcCtD
Labetalol—Diarrhoea—Prednisone—hematologic cancer	5.74e-05	0.000112	CcSEcCtD
Labetalol—Gastrointestinal pain—Methotrexate—hematologic cancer	5.73e-05	0.000112	CcSEcCtD
Labetalol—Nausea—Betamethasone—hematologic cancer	5.72e-05	0.000112	CcSEcCtD
Labetalol—Nausea—Dexamethasone—hematologic cancer	5.72e-05	0.000112	CcSEcCtD
Labetalol—Hypotension—Doxorubicin—hematologic cancer	5.67e-05	0.000111	CcSEcCtD
Labetalol—Fatigue—Epirubicin—hematologic cancer	5.65e-05	0.000111	CcSEcCtD
Labetalol—Pain—Epirubicin—hematologic cancer	5.61e-05	0.00011	CcSEcCtD
Labetalol—Constipation—Epirubicin—hematologic cancer	5.61e-05	0.00011	CcSEcCtD
Labetalol—Urticaria—Methotrexate—hematologic cancer	5.57e-05	0.000109	CcSEcCtD
Labetalol—Dizziness—Prednisone—hematologic cancer	5.54e-05	0.000109	CcSEcCtD
Labetalol—Abdominal pain—Methotrexate—hematologic cancer	5.54e-05	0.000108	CcSEcCtD
Labetalol—Body temperature increased—Methotrexate—hematologic cancer	5.54e-05	0.000108	CcSEcCtD
Labetalol—Paraesthesia—Doxorubicin—hematologic cancer	5.45e-05	0.000107	CcSEcCtD
Labetalol—Dyspnoea—Doxorubicin—hematologic cancer	5.41e-05	0.000106	CcSEcCtD
Labetalol—Feeling abnormal—Epirubicin—hematologic cancer	5.4e-05	0.000106	CcSEcCtD
Labetalol—Somnolence—Doxorubicin—hematologic cancer	5.39e-05	0.000106	CcSEcCtD
Labetalol—Gastrointestinal pain—Epirubicin—hematologic cancer	5.36e-05	0.000105	CcSEcCtD
Labetalol—Dyspepsia—Doxorubicin—hematologic cancer	5.34e-05	0.000105	CcSEcCtD
Labetalol—Vomiting—Prednisone—hematologic cancer	5.33e-05	0.000104	CcSEcCtD
Labetalol—Rash—Prednisone—hematologic cancer	5.29e-05	0.000103	CcSEcCtD
Labetalol—Dermatitis—Prednisone—hematologic cancer	5.28e-05	0.000103	CcSEcCtD
Labetalol—Headache—Prednisone—hematologic cancer	5.25e-05	0.000103	CcSEcCtD
Labetalol—Fatigue—Doxorubicin—hematologic cancer	5.23e-05	0.000102	CcSEcCtD
Labetalol—Urticaria—Epirubicin—hematologic cancer	5.21e-05	0.000102	CcSEcCtD
Labetalol—Pain—Doxorubicin—hematologic cancer	5.19e-05	0.000102	CcSEcCtD
Labetalol—Constipation—Doxorubicin—hematologic cancer	5.19e-05	0.000102	CcSEcCtD
Labetalol—Abdominal pain—Epirubicin—hematologic cancer	5.18e-05	0.000101	CcSEcCtD
Labetalol—Body temperature increased—Epirubicin—hematologic cancer	5.18e-05	0.000101	CcSEcCtD
Labetalol—Hypersensitivity—Methotrexate—hematologic cancer	5.16e-05	0.000101	CcSEcCtD
Labetalol—Asthenia—Methotrexate—hematologic cancer	5.03e-05	9.84e-05	CcSEcCtD
Labetalol—Feeling abnormal—Doxorubicin—hematologic cancer	5e-05	9.79e-05	CcSEcCtD
Labetalol—Nausea—Prednisone—hematologic cancer	4.98e-05	9.75e-05	CcSEcCtD
Labetalol—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.96e-05	9.71e-05	CcSEcCtD
Labetalol—Pruritus—Methotrexate—hematologic cancer	4.96e-05	9.71e-05	CcSEcCtD
Labetalol—Hypersensitivity—Epirubicin—hematologic cancer	4.83e-05	9.46e-05	CcSEcCtD
Labetalol—Urticaria—Doxorubicin—hematologic cancer	4.82e-05	9.44e-05	CcSEcCtD
Labetalol—Abdominal pain—Doxorubicin—hematologic cancer	4.8e-05	9.39e-05	CcSEcCtD
Labetalol—Body temperature increased—Doxorubicin—hematologic cancer	4.8e-05	9.39e-05	CcSEcCtD
Labetalol—Diarrhoea—Methotrexate—hematologic cancer	4.79e-05	9.39e-05	CcSEcCtD
Labetalol—Asthenia—Epirubicin—hematologic cancer	4.7e-05	9.21e-05	CcSEcCtD
Labetalol—Pruritus—Epirubicin—hematologic cancer	4.64e-05	9.08e-05	CcSEcCtD
Labetalol—Dizziness—Methotrexate—hematologic cancer	4.63e-05	9.07e-05	CcSEcCtD
Labetalol—Diarrhoea—Epirubicin—hematologic cancer	4.49e-05	8.78e-05	CcSEcCtD
Labetalol—Hypersensitivity—Doxorubicin—hematologic cancer	4.47e-05	8.75e-05	CcSEcCtD
Labetalol—Vomiting—Methotrexate—hematologic cancer	4.46e-05	8.72e-05	CcSEcCtD
Labetalol—Rash—Methotrexate—hematologic cancer	4.42e-05	8.65e-05	CcSEcCtD
Labetalol—Dermatitis—Methotrexate—hematologic cancer	4.41e-05	8.64e-05	CcSEcCtD
Labetalol—Headache—Methotrexate—hematologic cancer	4.39e-05	8.59e-05	CcSEcCtD
Labetalol—Asthenia—Doxorubicin—hematologic cancer	4.35e-05	8.52e-05	CcSEcCtD
Labetalol—Dizziness—Epirubicin—hematologic cancer	4.34e-05	8.49e-05	CcSEcCtD
Labetalol—Pruritus—Doxorubicin—hematologic cancer	4.29e-05	8.4e-05	CcSEcCtD
Labetalol—Vomiting—Epirubicin—hematologic cancer	4.17e-05	8.16e-05	CcSEcCtD
Labetalol—Nausea—Methotrexate—hematologic cancer	4.16e-05	8.15e-05	CcSEcCtD
Labetalol—Diarrhoea—Doxorubicin—hematologic cancer	4.15e-05	8.13e-05	CcSEcCtD
Labetalol—Rash—Epirubicin—hematologic cancer	4.13e-05	8.09e-05	CcSEcCtD
Labetalol—Dermatitis—Epirubicin—hematologic cancer	4.13e-05	8.09e-05	CcSEcCtD
Labetalol—Headache—Epirubicin—hematologic cancer	4.11e-05	8.04e-05	CcSEcCtD
Labetalol—Dizziness—Doxorubicin—hematologic cancer	4.01e-05	7.85e-05	CcSEcCtD
Labetalol—Nausea—Epirubicin—hematologic cancer	3.9e-05	7.63e-05	CcSEcCtD
Labetalol—Vomiting—Doxorubicin—hematologic cancer	3.86e-05	7.55e-05	CcSEcCtD
Labetalol—Rash—Doxorubicin—hematologic cancer	3.83e-05	7.49e-05	CcSEcCtD
Labetalol—Dermatitis—Doxorubicin—hematologic cancer	3.82e-05	7.48e-05	CcSEcCtD
Labetalol—Headache—Doxorubicin—hematologic cancer	3.8e-05	7.44e-05	CcSEcCtD
Labetalol—Nausea—Doxorubicin—hematologic cancer	3.6e-05	7.06e-05	CcSEcCtD
Labetalol—CYP2D6—Metabolism—TXN—hematologic cancer	2.03e-05	0.000236	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—STAT1—hematologic cancer	2.02e-05	0.000235	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—BRAF—hematologic cancer	2.01e-05	0.000234	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CCL2—hematologic cancer	2e-05	0.000233	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CREB1—hematologic cancer	2e-05	0.000233	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL6R—hematologic cancer	1.99e-05	0.000232	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CCL2—hematologic cancer	1.99e-05	0.000232	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL6R—hematologic cancer	1.99e-05	0.000231	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SPHK1—hematologic cancer	1.98e-05	0.000231	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CREBBP—hematologic cancer	1.98e-05	0.000231	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—STAT1—hematologic cancer	1.98e-05	0.00023	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PIK3R1—hematologic cancer	1.96e-05	0.000229	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CCL2—hematologic cancer	1.96e-05	0.000228	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL6R—hematologic cancer	1.95e-05	0.000227	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PIK3R1—hematologic cancer	1.92e-05	0.000224	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—JAK2—hematologic cancer	1.91e-05	0.000222	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—UGT1A1—hematologic cancer	1.91e-05	0.000222	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—MAP2K1—hematologic cancer	1.9e-05	0.000221	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MAP2K1—hematologic cancer	1.89e-05	0.00022	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GRB2—hematologic cancer	1.89e-05	0.00022	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PIK3CD—hematologic cancer	1.89e-05	0.00022	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PDGFA—hematologic cancer	1.89e-05	0.00022	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PIK3CD—hematologic cancer	1.88e-05	0.000219	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—JAK2—hematologic cancer	1.87e-05	0.000217	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—PIK3CA—hematologic cancer	1.86e-05	0.000217	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KITLG—hematologic cancer	1.86e-05	0.000217	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—MAP2K1—hematologic cancer	1.86e-05	0.000216	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SLC22A1—hematologic cancer	1.85e-05	0.000216	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CRABP1—hematologic cancer	1.85e-05	0.000216	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GRB2—hematologic cancer	1.85e-05	0.000215	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PIK3CD—hematologic cancer	1.85e-05	0.000215	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PDGFA—hematologic cancer	1.85e-05	0.000215	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—KRAS—hematologic cancer	1.84e-05	0.000214	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KITLG—hematologic cancer	1.82e-05	0.000212	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—STAT5A—hematologic cancer	1.82e-05	0.000212	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PIK3CB—hematologic cancer	1.81e-05	0.000211	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ALOX5—hematologic cancer	1.81e-05	0.00021	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CDKN2B—hematologic cancer	1.8e-05	0.00021	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—FGF2—hematologic cancer	1.8e-05	0.00021	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PIK3R1—hematologic cancer	1.78e-05	0.000208	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—STAT5A—hematologic cancer	1.78e-05	0.000207	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PIK3R1—hematologic cancer	1.77e-05	0.000207	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	1.77e-05	0.000206	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CDKN2B—hematologic cancer	1.76e-05	0.000205	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NUP98—hematologic cancer	1.75e-05	0.000204	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PIK3R1—hematologic cancer	1.74e-05	0.000203	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CD86—hematologic cancer	1.74e-05	0.000203	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	1.73e-05	0.000202	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—JAK2—hematologic cancer	1.72e-05	0.000201	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—HES1—hematologic cancer	1.72e-05	0.0002	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	1.71e-05	0.000199	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CD86—hematologic cancer	1.7e-05	0.000198	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ADCY7—hematologic cancer	1.7e-05	0.000198	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NCOA3—hematologic cancer	1.7e-05	0.000198	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	1.7e-05	0.000197	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PIK3CA—hematologic cancer	1.69e-05	0.000197	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	1.69e-05	0.000197	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	1.69e-05	0.000197	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NUP214—hematologic cancer	1.69e-05	0.000196	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MDM2—hematologic cancer	1.68e-05	0.000196	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—HES1—hematologic cancer	1.68e-05	0.000196	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	1.67e-05	0.000195	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	1.67e-05	0.000194	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	1.66e-05	0.000194	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	1.66e-05	0.000194	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	1.65e-05	0.000192	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	1.65e-05	0.000192	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ABCG2—hematologic cancer	1.65e-05	0.000192	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MTR—hematologic cancer	1.65e-05	0.000192	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	1.65e-05	0.000192	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PIK3CB—hematologic cancer	1.64e-05	0.000191	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MTOR—hematologic cancer	1.64e-05	0.000191	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	1.64e-05	0.000191	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	1.63e-05	0.00019	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	1.63e-05	0.00019	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	1.63e-05	0.00019	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	1.63e-05	0.00019	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	1.63e-05	0.000189	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ENO2—hematologic cancer	1.62e-05	0.000189	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	1.61e-05	0.000187	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	1.6e-05	0.000186	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	1.6e-05	0.000186	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	1.6e-05	0.000186	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTT1—hematologic cancer	1.57e-05	0.000183	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—HRAS—hematologic cancer	1.56e-05	0.000182	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CDKN1B—hematologic cancer	1.54e-05	0.000179	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SDC1—hematologic cancer	1.54e-05	0.000179	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	1.52e-05	0.000177	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—AKT1—hematologic cancer	1.52e-05	0.000177	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	1.51e-05	0.000176	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CASP3—hematologic cancer	1.51e-05	0.000175	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TERT—hematologic cancer	1.51e-05	0.000175	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL2—hematologic cancer	1.5e-05	0.000175	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—IL6—hematologic cancer	1.5e-05	0.000174	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	1.49e-05	0.000173	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	1.48e-05	0.000172	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TERT—hematologic cancer	1.47e-05	0.000172	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	1.47e-05	0.000171	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CCND1—hematologic cancer	1.47e-05	0.000171	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—JUN—hematologic cancer	1.46e-05	0.00017	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	1.44e-05	0.000167	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	1.44e-05	0.000167	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CDKN1A—hematologic cancer	1.42e-05	0.000165	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PTEN—hematologic cancer	1.42e-05	0.000165	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	1.41e-05	0.000164	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MAPK8—hematologic cancer	1.38e-05	0.000161	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	1.38e-05	0.000161	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—AKT1—hematologic cancer	1.38e-05	0.000161	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	1.37e-05	0.000159	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	1.35e-05	0.000157	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—EP300—hematologic cancer	1.35e-05	0.000157	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	1.34e-05	0.000156	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	1.34e-05	0.000156	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FN1—hematologic cancer	1.33e-05	0.000154	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	1.31e-05	0.000153	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SRC—hematologic cancer	1.31e-05	0.000153	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—BAD—hematologic cancer	1.31e-05	0.000153	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	1.31e-05	0.000153	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NQO1—hematologic cancer	1.31e-05	0.000152	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CD44—hematologic cancer	1.31e-05	0.000152	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	1.3e-05	0.000151	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FN1—hematologic cancer	1.3e-05	0.000151	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—BAD—hematologic cancer	1.28e-05	0.000149	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	1.28e-05	0.000149	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—VEGFA—hematologic cancer	1.28e-05	0.000149	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CD80—hematologic cancer	1.27e-05	0.000148	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	1.27e-05	0.000148	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	1.27e-05	0.000148	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KIT—hematologic cancer	1.27e-05	0.000148	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	1.27e-05	0.000148	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—STAT3—hematologic cancer	1.27e-05	0.000147	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NRAS—hematologic cancer	1.26e-05	0.000147	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	1.25e-05	0.000145	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CD80—hematologic cancer	1.24e-05	0.000145	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	1.24e-05	0.000145	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KIT—hematologic cancer	1.24e-05	0.000145	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	1.24e-05	0.000145	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYCS—hematologic cancer	1.24e-05	0.000144	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.23e-05	0.000143	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	1.22e-05	0.000142	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	1.22e-05	0.000141	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MAPK3—hematologic cancer	1.21e-05	0.000141	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	1.21e-05	0.000141	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	1.19e-05	0.000139	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	1.19e-05	0.000138	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	1.18e-05	0.000138	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	1.18e-05	0.000138	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	1.18e-05	0.000137	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	1.18e-05	0.000137	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MYC—hematologic cancer	1.18e-05	0.000137	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TGFB1—hematologic cancer	1.17e-05	0.000137	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	1.17e-05	0.000136	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	1.16e-05	0.000135	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	1.15e-05	0.000134	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	1.15e-05	0.000134	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	1.12e-05	0.000131	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	1.12e-05	0.00013	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.1e-05	0.000129	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	1.1e-05	0.000128	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	1.09e-05	0.000127	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	1.09e-05	0.000127	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.09e-05	0.000127	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—KRAS—hematologic cancer	1.09e-05	0.000127	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	1.08e-05	0.000126	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	1.07e-05	0.000124	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	1.07e-05	0.000124	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	1.05e-05	0.000123	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	1.04e-05	0.000122	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.03e-05	0.00012	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	1.03e-05	0.00012	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	1.02e-05	0.000119	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	1e-05	0.000117	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	1e-05	0.000117	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTM1—hematologic cancer	1e-05	0.000117	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NCOR1—hematologic cancer	1e-05	0.000117	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	9.99e-06	0.000116	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PIK3CA—hematologic cancer	9.99e-06	0.000116	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	9.82e-06	0.000114	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	9.78e-06	0.000114	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	9.72e-06	0.000113	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	9.72e-06	0.000113	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TP53—hematologic cancer	9.66e-06	0.000112	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	9.51e-06	0.000111	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	9.51e-06	0.000111	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	9.28e-06	0.000108	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—HRAS—hematologic cancer	9.24e-06	0.000108	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	9.13e-06	0.000106	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	9.08e-06	0.000106	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	9.03e-06	0.000105	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	8.94e-06	0.000104	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL2—hematologic cancer	8.93e-06	0.000104	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	8.93e-06	0.000104	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	8.89e-06	0.000103	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MTHFR—hematologic cancer	8.85e-06	0.000103	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL6—hematologic cancer	8.84e-06	0.000103	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	8.83e-06	0.000103	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	8.75e-06	0.000102	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL2—hematologic cancer	8.74e-06	0.000102	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	8.71e-06	0.000101	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	8.69e-06	0.000101	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—JUN—hematologic cancer	8.69e-06	0.000101	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	8.52e-06	9.91e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—JUN—hematologic cancer	8.5e-06	9.89e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	8.42e-06	9.8e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	8.4e-06	9.78e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	8.24e-06	9.59e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	8.22e-06	9.57e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	8.22e-06	9.57e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	8.2e-06	9.54e-05	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—AKT1—hematologic cancer	8.16e-06	9.5e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	8.04e-06	9.36e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	8.02e-06	9.34e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EP300—hematologic cancer	8.01e-06	9.33e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EP300—hematologic cancer	7.84e-06	9.13e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SRC—hematologic cancer	7.79e-06	9.07e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SRC—hematologic cancer	7.62e-06	8.87e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	7.59e-06	8.84e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	7.51e-06	8.75e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	7.5e-06	8.73e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	7.43e-06	8.66e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	7.42e-06	8.64e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	7.35e-06	8.56e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	7.33e-06	8.54e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	7.18e-06	8.36e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	7.02e-06	8.18e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MYC—hematologic cancer	6.98e-06	8.13e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	6.97e-06	8.11e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CREBBP—hematologic cancer	6.89e-06	8.02e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MYC—hematologic cancer	6.83e-06	7.95e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	6.81e-06	7.93e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	6.54e-06	7.61e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	6.45e-06	7.51e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ALB—hematologic cancer	6.45e-06	7.51e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	6.31e-06	7.35e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	6.17e-06	7.19e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	5.93e-06	6.9e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	5.8e-06	6.75e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TP53—hematologic cancer	5.73e-06	6.68e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	5.7e-06	6.63e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TP53—hematologic cancer	5.61e-06	6.53e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	5.48e-06	6.38e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	5.36e-06	6.25e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL6—hematologic cancer	5.25e-06	6.11e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL6—hematologic cancer	5.13e-06	5.98e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PTEN—hematologic cancer	4.92e-06	5.73e-05	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	4.84e-06	5.64e-05	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	4.74e-06	5.51e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—EP300—hematologic cancer	4.69e-06	5.47e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	3.47e-06	4.04e-05	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—AKT1—hematologic cancer	2.84e-06	3.3e-05	CbGpPWpGaD
